INT79299

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 18
Disease Relevance 8.27
Pain Relevance 3.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (NXT1) intracellular (NXT1) cytoplasm (NXT1)
Anatomy Link Frequency
joint 1
osteoblast 1
arms 1
face 1
knee 1
NXT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
alcohol 12 99.28 Very High Very High Very High
backache 25 98.40 Very High Very High Very High
headache 4 97.36 Very High Very High Very High
visual analogue scale 6 96.28 Very High Very High Very High
Analgesic 6 96.20 Very High Very High Very High
Osteoarthritis 249 93.76 High High
Pain score 2 89.12 High High
Pain 24 87.60 High High
dexamethasone 21 83.08 Quite High
Spinal cord 6 81.00 Quite High
Disease Link Frequency Relevance Heat
Hypercalcemia 104 100.00 Very High Very High Very High
Low Back Pain 25 98.56 Very High Very High Very High
Osteoporosis 244 97.74 Very High Very High Very High
Headache 4 97.36 Very High Very High Very High
Vomiting 4 96.84 Very High Very High Very High
Cancer 10 94.24 High High
Osteophyte 12 93.80 High High
Osteoarthritis 246 93.76 High High
Pain 21 88.88 High High
Alcohol Addiction 2 87.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Not all of the subjects decreased their beer intake on NTX, and some subjects drank more beer.
Negative_regulation (decreased) of NTX
1) Confidence 0.32 Published 1999 Journal Alcohol. Clin. Exp. Res. Section Abstract Doc Link 10069545 Disease Relevance 0.28 Pain Relevance 0.38
NTX decreased urges to consume alcohol.
Negative_regulation (decreased) of NTX associated with alcohol
2) Confidence 0.32 Published 1999 Journal Alcohol. Clin. Exp. Res. Section Abstract Doc Link 10069545 Disease Relevance 0.21 Pain Relevance 0.20
A decrease in serum and urinary NTx was associated with improvement of low back pain, suggesting that despite the absence of vertebral fractures, bone resorption due to osteoporosis may cause low back pain.
Negative_regulation (decrease) of NTx associated with low back pain, osteoporosis, hypercalcemia and backache
3) Confidence 0.06 Published 2010 Journal J Clin Neurosci Section Abstract Doc Link 20044258 Disease Relevance 1.13 Pain Relevance 0.65
DEXA did not increase significantly, but serum and urinary NTx were decreased (-51.4% and -62.0%, respectively) after 4 months of risedronate treatment (p<0.01).
Negative_regulation (decreased) of NTx
4) Confidence 0.06 Published 2010 Journal J Clin Neurosci Section Abstract Doc Link 20044258 Disease Relevance 0.82 Pain Relevance 0.65
Although the reduction in the urinary NTx level was significantly greater in the alendronate group than in the etidronate group, the reduction in the face scale score was transiently significantly greater in the etidronate group than in the alendronate group.
Negative_regulation (reduction) of NTx in face
5) Confidence 0.04 Published 2003 Journal Keio J Med Section Abstract Doc Link 14748475 Disease Relevance 0.56 Pain Relevance 0.43
Patients with less than a partial response showed a small but significant decrease in NTX-I (data not shown).
Negative_regulation (decrease) of NTX-I
6) Confidence 0.02 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0.35 Pain Relevance 0.10
The levels of the bone resorption marker NTX-I were reduced by approximately 50% after one treatment cycle in responding patients and remained relatively constant thereafter (Fig. 3B).
Negative_regulation (reduced) of NTX-I associated with hypercalcemia
7) Confidence 0.02 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0.27 Pain Relevance 0.12
One explanation for the biphasic development of the curve could be that an initial direct osteoblast stimulation caused by bortezomib is later counteracted by a decrease in total bone remodeling as indicated by a decrease in the bone resorption marker NTX-I.
Negative_regulation (decrease) of NTX-I in osteoblast associated with hypercalcemia and osteoporosis
8) Confidence 0.02 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0.45 Pain Relevance 0.09
Another subanalysis study by Garnero, et al.11 (the North America and European Union arms, n = 1,885) revealed that urinary levels of CTX-II and NTX-I decreased with risedronate treatment in a dose-dependent manner (Fig. 2).
Negative_regulation (decreased) of NTX-I in arms
9) Confidence 0.01 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.42 Pain Relevance 0.23
A larger RCT (n = 1,896, study period 2 years) by Bingham, et al.9 showed that risedronate at any doses (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) reduced urinary levels of CTX-II and NTX-I, but did not improve WOMAC scores, PGA scores, average number of days, and number of pills of analgesic medication taken per week, joint space width, and osteophyte development.
Negative_regulation (reduced) of NTX-I in joint associated with osteophyte and analgesic
10) Confidence 0.01 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.77 Pain Relevance 0.32
RESULTS: The addition of pamidronate to chemotherapy resulted in a significant reduction of NTx, IL-6 and paraprotein from the 3rd month and of beta2-microglobulin, CRP and pain from the 6th month of treatment.
Negative_regulation (reduction) of NTx
11) Confidence 0.01 Published 2000 Journal Eur. J. Haematol. Section Body Doc Link 11092464 Disease Relevance 0.24 Pain Relevance 0
During bisphosphonate therapy, significant decreases in Osteomark NTx, CrossLaps and calcium excretion were observed, which were not related to the clinical outcome.
Negative_regulation (decreases) of Osteomark NTx
12) Confidence 0.01 Published 1998 Journal Clin. Chem. Lab. Med. Section Abstract Doc Link 9877095 Disease Relevance 1.24 Pain Relevance 0.31
Both RCTs showed risedronate treatment reduced urinary levels of CTX-II and NTX-I,8,9 and a subanalysis study of the RCT (KOSTAR) by Garnero, et al.11 revealed that urinary levels of CTX-II, but not NTX-I, reached after 6 months of risedronate treatment were associated with radiological progression of knee OA at 24 months.
Negative_regulation (reduced) of NTX-I in knee associated with osteoarthritis
13) Confidence 0.01 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.69 Pain Relevance 0.31
Urinary N-telopeptide (NTX), a marker of bone resorption, was reduced by about 90%.
Negative_regulation (reduced) of NTX associated with hypercalcemia
14) Confidence 0.00 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.46 Pain Relevance 0
Within 12 hours, a dose-dependent decrease in NTX/creatinine ratio was observed.
Negative_regulation (decrease) of NTX
15) Confidence 0.00 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.10 Pain Relevance 0
Urinary NTX levels were reduced within 12 hours of dosing.
Negative_regulation (reduced) of NTX
16) Confidence 0.00 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.16 Pain Relevance 0
The NTX decline was greater than that of PYD and DPYD (maximum percent decrease: -71.3, -23.1 and -28.2, respectively).
Negative_regulation (decline) of NTX
17) Confidence 0.00 Published 2002 Journal Int. J. Biol. Markers Section Body Doc Link 12521128 Disease Relevance 0.06 Pain Relevance 0
RESULTS: PYD, DPYD and NTX showed a significant decrease lasting four weeks (p<0.01, <0.01 and <0.001, respectively).
Negative_regulation (decrease) of NTX
18) Confidence 0.00 Published 2002 Journal Int. J. Biol. Markers Section Body Doc Link 12521128 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox